Bihua Chen

Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston.

Putnam Investments LLC operates as an investment advisory company. The company was founded on May 14, 2009 and is headquartered in Boston, MA.

Asterion LLC manufactures chemical finishing products. The company was founded in January and is headquartered in Indianapolis, IN.

American Express Asset Management International (UK) is a global payments, network and travel firm which is headquartered in London, UK.

Cormorant Asset Management LLC (Cormorant) is an independent hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Bi Hua Chen in 2013. Cormorant provides discretionary investment advisory services to hedge funds, private equity funds and separately managed accounts. Investors in the Funds consist of institutional investors and other sophisticated investors.

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

Cormorant Asset Management LLC/Private Equity/ (Cormorant Asset Management) is a venture capital subsidiary of Cormorant Asset Management LP founded in 2013 by Bi Hua Chen. The firm is headquartered in Boston, Massachusetts.

North Tide Capital LLC is an independent hedge fund management firm headquartered in Boston, Massachusetts. The firm was founded by Conan Laughlin in 2010 as BCL Capital Management. North Tide Capital provides discretionary investment advisory services to institutional investors and other sophisticated investors.

Founded in 1998, Bellevue Research, Inc. is a fundamental equity investment research firm located in Boston. The firm is US investment research arm of Bellevue Asset Management AG, a privately-owned asset management group based in Zurich, Switzerland. Their ultimate parent is Bellevue Group AG. Bellevue research provides research to Bellevue Asset Management with coverage of the biotechnology, genetic engineering and pharmaceuticals sectors.

Helix Acquisition Corp. operates as a blank check company. It is a special purpose acquisition company which is incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on August 13, 2020 and is headquartered in Boston, MA.

Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation.

Atia Vision, Inc. provides medical device services. The company was founded in 2012 and is headquartered in Campbell, CA.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015.